PortalPublikationenRandomized trial of rifabutin-based triple therapy and high-...

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

Standard

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. / Miehlke, S; Hansky, K; Schneider-Brachert, W; Kirsch, C; Morgner, A; Madisch, A; Kuhlisch, E; Bästlein, E; Jacobs, E; Bayerdörffer, E; Lehn, N; Stolte, M.

in: ALIMENT PHARM THER, Jahrgang 24, Nr. 2, 15.07.2006, S. 395-403.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Miehlke, S, Hansky, K, Schneider-Brachert, W, Kirsch, C, Morgner, A, Madisch, A, Kuhlisch, E, Bästlein, E, Jacobs, E, Bayerdörffer, E, Lehn, N & Stolte, M 2006, 'Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin', ALIMENT PHARM THER, Jg. 24, Nr. 2, S. 395-403. https://doi.org/10.1111/j.1365-2036.2006.02993.x

APA

Miehlke, S., Hansky, K., Schneider-Brachert, W., Kirsch, C., Morgner, A., Madisch, A., Kuhlisch, E., Bästlein, E., Jacobs, E., Bayerdörffer, E., Lehn, N., & Stolte, M. (2006). Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. ALIMENT PHARM THER, 24(2), 395-403. https://doi.org/10.1111/j.1365-2036.2006.02993.x

Vancouver

Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. ALIMENT PHARM THER. 2006 Jul 15;24(2):395-403. https://doi.org/10.1111/j.1365-2036.2006.02993.x

Bibtex

@article{bcd737f5e56744d2ad196aa562437a41,
title = "Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin",
abstract = "BACKGROUND: The clinical management of Helicobacter pylori infected patients who failed standard eradication therapies remains a challenge.AIM: To investigate the efficacy of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of H. pylori, and the correlation between cytochrome P450 2C19 (CYP2C19) polymorphisms and treatment outcome.METHODS: Patients infected with H. pylori resistant to both metronidazole and clarithromycin (n = 145) were randomized to either esomeprazole 20 mg, rifabutin 150 mg and amoxicillin 1 g, each given b.d. for 7 days (ERA), or to omeprazole 40 mg and amoxicillin 1000 mg, each given t.d.s. for 14 days (OA). Crossover therapy was offered in cases of persistent infection. CYP2C19 polymorphisms were determined by polymerase chain reaction restriction fragment length polymorphism.RESULTS: Intention-to-treat and per-protocol eradication rates were: ERA 74% (62.4-83.6) and 78% (66.7-87.3); high-dose OA 70% (57.5-79.7) and 75% (62.5-84.5). Crossover therapy was successful in seven of 10 patients with ERA and in eight of 10 patients with OA. Premature discontinuation of treatment occurred in 2% and 5% of patients, respectively. There was only a non-significant trend to lower eradication rates in homozygous extensive metabolizers.CONCLUSIONS: Triple therapy with esomeprazole, rifabutin and amoxicillin and high-dose omeprazole/amoxicillin are comparable and effective and safe for rescue therapy of H. pylori regardless of the patient's CYP2C19 genotype.",
keywords = "Adolescent, Adult, Aged, Amoxicillin, Anti-Bacterial Agents, Anti-Ulcer Agents, Clarithromycin, Cross-Over Studies, Drug Resistance, Bacterial, Drug Therapy, Combination, Esomeprazole, Female, Helicobacter Infections, Helicobacter pylori, Humans, Male, Metronidazole, Middle Aged, Omeprazole, Prospective Studies, Rifabutin, Treatment Outcome, Journal Article, Multicenter Study, Randomized Controlled Trial",
author = "S Miehlke and K Hansky and W Schneider-Brachert and C Kirsch and A Morgner and A Madisch and E Kuhlisch and E B{\"a}stlein and E Jacobs and E Bayerd{\"o}rffer and N Lehn and M Stolte",
year = "2006",
month = jul,
day = "15",
doi = "10.1111/j.1365-2036.2006.02993.x",
language = "English",
volume = "24",
pages = "395--403",
journal = "ALIMENT PHARM THER",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

AU - Miehlke, S

AU - Hansky, K

AU - Schneider-Brachert, W

AU - Kirsch, C

AU - Morgner, A

AU - Madisch, A

AU - Kuhlisch, E

AU - Bästlein, E

AU - Jacobs, E

AU - Bayerdörffer, E

AU - Lehn, N

AU - Stolte, M

PY - 2006/7/15

Y1 - 2006/7/15

N2 - BACKGROUND: The clinical management of Helicobacter pylori infected patients who failed standard eradication therapies remains a challenge.AIM: To investigate the efficacy of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of H. pylori, and the correlation between cytochrome P450 2C19 (CYP2C19) polymorphisms and treatment outcome.METHODS: Patients infected with H. pylori resistant to both metronidazole and clarithromycin (n = 145) were randomized to either esomeprazole 20 mg, rifabutin 150 mg and amoxicillin 1 g, each given b.d. for 7 days (ERA), or to omeprazole 40 mg and amoxicillin 1000 mg, each given t.d.s. for 14 days (OA). Crossover therapy was offered in cases of persistent infection. CYP2C19 polymorphisms were determined by polymerase chain reaction restriction fragment length polymorphism.RESULTS: Intention-to-treat and per-protocol eradication rates were: ERA 74% (62.4-83.6) and 78% (66.7-87.3); high-dose OA 70% (57.5-79.7) and 75% (62.5-84.5). Crossover therapy was successful in seven of 10 patients with ERA and in eight of 10 patients with OA. Premature discontinuation of treatment occurred in 2% and 5% of patients, respectively. There was only a non-significant trend to lower eradication rates in homozygous extensive metabolizers.CONCLUSIONS: Triple therapy with esomeprazole, rifabutin and amoxicillin and high-dose omeprazole/amoxicillin are comparable and effective and safe for rescue therapy of H. pylori regardless of the patient's CYP2C19 genotype.

AB - BACKGROUND: The clinical management of Helicobacter pylori infected patients who failed standard eradication therapies remains a challenge.AIM: To investigate the efficacy of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of H. pylori, and the correlation between cytochrome P450 2C19 (CYP2C19) polymorphisms and treatment outcome.METHODS: Patients infected with H. pylori resistant to both metronidazole and clarithromycin (n = 145) were randomized to either esomeprazole 20 mg, rifabutin 150 mg and amoxicillin 1 g, each given b.d. for 7 days (ERA), or to omeprazole 40 mg and amoxicillin 1000 mg, each given t.d.s. for 14 days (OA). Crossover therapy was offered in cases of persistent infection. CYP2C19 polymorphisms were determined by polymerase chain reaction restriction fragment length polymorphism.RESULTS: Intention-to-treat and per-protocol eradication rates were: ERA 74% (62.4-83.6) and 78% (66.7-87.3); high-dose OA 70% (57.5-79.7) and 75% (62.5-84.5). Crossover therapy was successful in seven of 10 patients with ERA and in eight of 10 patients with OA. Premature discontinuation of treatment occurred in 2% and 5% of patients, respectively. There was only a non-significant trend to lower eradication rates in homozygous extensive metabolizers.CONCLUSIONS: Triple therapy with esomeprazole, rifabutin and amoxicillin and high-dose omeprazole/amoxicillin are comparable and effective and safe for rescue therapy of H. pylori regardless of the patient's CYP2C19 genotype.

KW - Adolescent

KW - Adult

KW - Aged

KW - Amoxicillin

KW - Anti-Bacterial Agents

KW - Anti-Ulcer Agents

KW - Clarithromycin

KW - Cross-Over Studies

KW - Drug Resistance, Bacterial

KW - Drug Therapy, Combination

KW - Esomeprazole

KW - Female

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Humans

KW - Male

KW - Metronidazole

KW - Middle Aged

KW - Omeprazole

KW - Prospective Studies

KW - Rifabutin

KW - Treatment Outcome

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

U2 - 10.1111/j.1365-2036.2006.02993.x

DO - 10.1111/j.1365-2036.2006.02993.x

M3 - SCORING: Journal article

C2 - 16842467

VL - 24

SP - 395

EP - 403

JO - ALIMENT PHARM THER

JF - ALIMENT PHARM THER

SN - 0269-2813

IS - 2

ER -